Home » Topics » Regulatory » Patents

Patents
RSS

Clarion prepares novel compounds for cancer, psoriasis and inflammation

Nov. 20, 1998

Agents for nephritis in the Tsumura pipeline

Nov. 19, 1998

Wide series of 5-HT antagonists from Eisai useful as antispastic agents, central muscle relaxants

Nov. 19, 1998

Mercian presents HIV protease inhibitors produced by fungus

Nov. 19, 1998

Anti-H. pylori cephems in development at Takeda

Nov. 19, 1998

Endothelin antagonists a focus of R&D at Merck KGaA

Nov. 19, 1998

Potent and selective 5-HT1A/5-HT1B/5-HT1D receptor antagonists discovered at Pierre Fabre

Nov. 18, 1998

New thiazolidinediones for diabetes reported in patent literature by Boehringer Mannheim

Nov. 18, 1998

Synthelabo discloses orally active human thrombin inhibitors

Nov. 18, 1998

5-HT antagonists in development at Synthelabo for cardiovascular and other disorders

Nov. 18, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
Recludix presents STAT1/3 inhibitors for dermatological diseases
BioWorld Science
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.